Skip to main content
Clinical Trials/CTRI/2021/07/035277
CTRI/2021/07/035277
Other
Phase 3

An Open Label, Multicentre, Single Arm Clinical Trial to Determine the Efficacy and Safety of Hemoday Manufactured By G. C. Chemie PharmieLtd in Iron Deficiency Anemia in Pregnant Women.

GC Chemie Pharmie Ltd0 sites4 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
GC Chemie Pharmie Ltd
Enrollment
4
Status
Other
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 31, 2022
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
GC Chemie Pharmie Ltd

Eligibility Criteria

Inclusion Criteria

  • Age ââ?°Â¥ 18 years at recruitment.
  • Pregnant women between 16 and 28 weeks of gestation diagnosed with Iron deficiency Anemia
  • Haemoglobin between 7 to 9gm%
  • Treatment New Patients
  • Singleton Pregnancy
  • Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF); willingness and capability to complete all the study procedures.

Exclusion Criteria

  • Within two months of starting iron therapy.
  • Multiple pregnancy
  • History of previous or repeated blood transfusion.
  • History of haematological disease.
  • Hemodynamic instability or clinically perceived or anticipated need of blood transfusion
  • Risk of preterm labour.
  • Pregnant women with any other comorbidities such as renal or hepatic impairment, cardiovascular diseases, preeclampsia, GDM, thyroid disorders, acid peptic disease, esophagitis and malabsorption syndrome.
  • Treatment with any other investigational drug in the last 1 month before study entry
  • Current usage of iron supplement
  • High risk pregnancy.

Outcomes

Primary Outcomes

Not specified

Similar Trials